Showing 685 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

Pharmaceutical industry

Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

Editor's pick
Gilead press release
22 April 2014
PrEP

Px Wire: Long-Acting Injectables

Editor's pick
AVAC
17 April 2014
New & experimental HIV treatments

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Editor's pick
Bristol-Myers Squibb press release
15 April 2014
The search for a cure

Transplant Drugs May Fight HIV Reservoir

Editor's pick
AIDSMeds
14 April 2014
New & experimental HIV treatments

Nano-sized drug particles to expand HIV treatment further

Editor's pick
Medical Xpress
9 April 2014
Injectable & long-acting HIV treatment

Long-acting HIV drugs advanced to overcome adherence challenge

Editor's pick
Nature Medicine
8 April 2014
Access to healthcare

Viiv Healthcare licenses dolutegravir (Tivicay) to Medicines Patent Pool

Editor's pick
Viiv Healthcare press release
2 April 2014
New & experimental HIV treatments

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Editor's pick
Janssen press release
2 April 2014
Changing treatment

Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

Editor's pick
HIV i-Base
10 March 2014
The search for a cure

HIV gene therapy using GM cells hailed a success after trial

Editor's pick
The Guardian
5 March 2014
New & experimental HIV treatments

UK: Once-daily HIV pill Tivicay from ViiV gets launch

Editor's pick
Pharma Times
5 February 2014
New & experimental HIV treatments

Researchers open door to new HIV therapy

Editor's pick
University of California Berkeley press release
30 January 2014
Clinical trials

Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely

Editor's pick
Forbes
22 January 2014
New & experimental HIV treatments

ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

Editor's pick
ViiV Healthcare press release
21 January 2014
The search for a cure

NIH-created toxin can kill HIV-infected cells that persist despite treatment

Editor's pick
Eurekalert Medicine & Health
10 January 2014
HIV treatment for children & young people

Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension

Editor's pick
Wall Street Journal
9 January 2014
New & experimental HIV treatments

Vertex's VX-765 holds promise for HIV treatment

Editor's pick
Motley Fool
7 January 2014
New & experimental HIV treatments

New anti-HIV drug target identified

Editor's pick
Medical Xpress
19 December 2013
New & experimental HIV treatments

Lupin launches HIV drug in the US

Editor's pick
The Hindu
19 December 2013
Changing treatment

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

Editor's pick
Gilead press release
16 December 2013
The search for a cure

Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load

Editor's pick
Sangamo Biosciences press release
10 December 2013
New & experimental HIV treatments

Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

Editor's pick
European Medicines Agency
26 November 2013
New & experimental HIV treatments

Gilead's Vitekta Gets Approval in European Union

Editor's pick
Wall Street Journal
19 November 2013
Treatment guidelines

Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

Editor's pick
AIDS Info
31 October 2013